EBOS GROUP LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.45 NZD | +1.90% |
|
+2.37% | -0.14% |
| Apr. 24 | Evans & Partners Starts Ebos Group at Positive, Price Target is NZ$40.94 | MT |
| Mar. 06 | Morgan Stanley Adjusts EBOS Group’s Price Target to AU$37 From AU$38, Keeps at Overweight | MT |
| Sales 2024 * | 13.91B 8.26B | Sales 2025 * | 12.34B 7.33B | Capitalization | 6.85B 4.07B |
|---|---|---|---|---|---|
| Net income 2024 * | 313M 186M | Net income 2025 * | 295M 175M | EV / Sales 2024 * | 0.58 x |
| Net Debt 2024 * | 1.17B 694M | Net Debt 2025 * | 1.03B 614M | EV / Sales 2025 * | 0.64 x |
| P/E ratio 2024 * |
22.1
x | P/E ratio 2025 * |
23.2
x | Employees | 5,000 |
| Yield 2024 * |
3.3% | Yield 2025 * |
3.2% | Free-Float | 80.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on EBOS Group Limited
More recommendations
More news
| 1 day | +1.90% | ||
| 1 week | +2.37% | ||
| Current month | +3.50% | ||
| 1 month | -0.42% | ||
| 3 months | -3.27% | ||
| 6 months | +2.75% | ||
| Current year | -0.14% |
1 week
33.86
35.49
1 month
33.5035.50
Current year
33.5037.90
1 year
33.5046.00
3 years
28.8946.75
5 years
18.4246.75
10 years
8.4446.75
| Managers | Title | Age | Since |
|---|---|---|---|
John Cullity
CEO | Chief Executive Officer | - | 14-06-30 |
Leonard Hansen
DFI | Director of Finance/CFO | - | - |
Mithran Naiker
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Bloom
BRD | Director/Board Member | 66 | 22-09-15 |
Liz Coutts
CHM | Chairman | 64 | 03-06-30 |
| Director/Board Member | - | 19-06-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 35.45 | +1.90% | 116,457 |
| 24-04-23 | 34.79 | -0.54% | 181,237 |
| 24-04-22 | 34.98 | +0.84% | 217,254 |
| 24-04-19 | 34.69 | +2.03% | 235,599 |
| 24-04-18 | 34 | -1.82% | 318,616 |
End-of-day quote New Zealand S.E., April 23, 2024
More quotes
EBOS Group Limited is a marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. The Company is a marketer and distributor of animal care brands. Its segments include Healthcare, Animal Care and Corporate. The Healthcare segment includes sales of healthcare products in a range of sectors, own brands, retail healthcare, pharmacy, hospital and logistic services and wholesale activities. The Animal Care segment includes sales of animal care products in a range of sectors, own manufactured and contract manufactured brands, retail, and wholesale activities. It sources and supplies a range of surgical, medical, and pharmaceutical products. Its Community Pharmacy business includes Symbion, ProPharma, Pharmacy Wholesalers Russells, TerryWhite Chemmart, Good Price Pharmacy Warehouse, healthSAVE, Ventura Health, Minfos, DoseAid, Intellipharm, Endeavour Consumer Health, and Red Seal. Its contract logistics include Healthcare Logistics and Clinect.
Sector
Pharmaceuticals
Calendar
2024-08-19
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
35.45
NZD
Average target price
37.57
NZD
Spread / Average Target
+5.98%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.14% | 3.99B | |
| +15.65% | 69.91B | |
| +2.72% | 25.14B | |
| +5.13% | 8.32B | |
| +6.10% | 8.07B | |
| -21.85% | 7.97B | |
| +0.73% | 4.56B | |
| +17.40% | 4.31B | |
| -2.34% | 3.87B | |
| +21.03% | 3.63B |
- Stock Market
- Equities
- EBO Stock
